Showing 1861-1870 of 3038 results for "".
- Norlase Announces Newly Appointed Distributors into Major European Marketshttps://modernod.com/news/norlase-announces-newly-appointed-distributors-into-major-european-markets/2478640/Norlase has announced new distributor partnerships developed to advance market growth and global expansion of the Norlase family of green laser systems into France, Germany, Italy, Spain, and the United Kingdom. “We’re thrilled to announce that most ophthalmologists in Europe will no
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- RetinAI Announces Collaboration with Novartis to Provide Artificial Intelligence Solutions in Ophthalmologyhttps://modernod.com/news/retinai-announces-collaboration-with-novartis-to-provide-artificial-intelligence-solutions-in-ophthalmology/2478636/RetinAI Medical announced a multi-year collaboration with Novartis Pharma under which RetinAI’s IT solutions and artificial intelligence tools will be used to support multiple projects in ophthalmology and digital health. Financial terms of the deal were not disclosed. The first pro
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi
- CDC Now Says Wearing a Mask Protects the Wearer, Toohttps://modernod.com/news/cdc-now-says-wearing-a-mask-protects-the-wearer-too/2478538/For months it has been clear that wearing a face mask reduces the transmission of COVID-19, because it prevents your respiratory droplets from spreading and potentially infecting other people. Now the Centers for Disease Control has highlighted another benefit of mask-wearing that many hoped or s
- FDA Fast-Tracks Novavax COVID-19 Vaccine NVXCoV2373https://modernod.com/news/fda-fast-tracks-novavax-covid-19-vaccine-nvxcov2373/2478517/Novavax said Monday that its experimental COVID-19 vaccine NVX-CoV2373 has received fast-track designation from the FDA. The company also reiterated that it expects to begin a pivotal phase 3 trial of the candidate in the US and Mexico by the end of November, data from which could be used to supp
- Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindnesshttps://modernod.com/news/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-for-treating-blindness/2478474/Novartis announced that it has acquired Vedere Bio, adding a new platform for AAV-based delivery of gene therapies and an optogenetics program. The acquisition will enable Novartis to advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
- Regenxbio to Receive $80 Million Milestone Payment from Novartishttps://modernod.com/news/regenxbio-to-receive-80-million-milestone-payment-from-novartis/2478475/Regenxbio announced that it will receive a milestone payment of $80 million from Novartis based upon the achievement of $1 billion in cumulative net sales of Zolgensma. Regenxbio expects to recognize this revenue in the third quarter of 2020. “Zolgensma is a transformative, one-time
- Norlase Announces FDA Clearance and US Launch of New LION Laser Systemhttps://modernod.com/news/norlase-announces-fda-clearance-and-u-s-launch-of-new-lion-laser-system/2478470/Norlase announced the 510(k) clearance from the FDA and the immediate commercial launch of Norlase LION, a green laser photocoagulator fully-integrated into a Keeler indirect ophthalmoscope. Unlike other laser indirect ophthalmoscopes that require a fiber optic connection to a laser source